US equities
|
SPCX
$167.24
▲+5.21%
NVDA
$237.09
▲+1.34%
MU
$1,066.80
▼-0.75%
TSLA
$375.86
▲+1.42%
MSFT
$525.87
▲+1.61%
INTC
$117.06
▼-1.90%
SNDK
$1,721.36
▲+0.08%
META
$742.01
▲+1.91%
SPCX
$167.24
▲+5.21%
NVDA
$237.09
▲+1.34%
MU
$1,066.80
▼-0.75%
TSLA
$375.86
▲+1.42%
MSFT
$525.87
▲+1.61%
INTC
$117.06
▼-1.90%
SNDK
$1,721.36
▲+0.08%
META
$742.01
▲+1.91%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Sema4 Holdings Corp. - Warrant
(NQ:
SMFRW
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Jan 9, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sema4 Holdings Corp. - Warrant
Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance
January 09, 2023
From
GeneDx Holdings Corp.
Via
GlobeNewswire
Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference
December 30, 2022
Sema4|GeneDx President & Chief Executive Officer, Katherine Stueland, to deliver presentation
From
Sema4
Via
GlobeNewswire
New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU
December 05, 2022
Data underscores the value of mitochondrial DNA testing and the opportunity to improve health outcomes for critically ill newborns with early medical intervention
From
Sema4
Via
GlobeNewswire
Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction
November 14, 2022
From
Sema4
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bed Bath & Beyond, Sema4, Medtronic, and Palantir and Encourages Investors to Contact the Firm
November 06, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022
November 04, 2022
From
Sema4
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kohl’s, Bed Bath & Beyond, Sema4, and Medtronic and Encourages Investors to Contact the Firm
October 31, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies
October 31, 2022
Guideline adoption can help end the diagnostic odyssey experienced by many families
From
Sema4
Via
GlobeNewswire
Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns
October 27, 2022
From
Sema4
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Kohl’s, Bed Bath & Beyond, Sema4, and Medtronic and Encourages Investors to Contact the Firm
October 26, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels
October 26, 2022
Exome and genome tests report 30% fewer inconclusive results and a higher diagnostic yield compared to multi-gene panel tests; research to be presented at American Society of Human Genetics Annual...
From
Sema4
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against TuSimple, Kohl’s, Bed Bath & Beyond, and Sema4 and Encourages Investors to Contact the Firm
October 21, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sema4, Medtronic, Palantir, and Fulgent and Encourages Investors to Contact the Firm
October 16, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum Disorders
October 13, 2022
From
Sema4
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sema4, Medtronic, Palantir, and Fulgent and Encourages Investors to Contact the Firm
October 11, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sema4, Medtronic, Palantir, and Fulgent and Encourages Investors to Contact the Firm
October 06, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Sema4|GeneDx To Provide Whole Genome Sequencing and Interpretation Services for Landmark Genomic Newborn Screening Study
October 05, 2022
The largest study of its kind in North America, GUARDIAN is expected to improve population health by identifying more than 250 preventable and treatable conditions, many of which are not covered today...
From
Sema4
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sema4, Medtronic, Palantir, and Fulgent and Encourages Investors to Contact the Firm
October 02, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
INVESTOR NOTICE: Sema4 Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SMFR; SMFRW
September 20, 2022
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Investor Alert: Sema4 Holdings Corp. (SMFR, SMFRW) Class Action - Bronstein, Gewirtz & Grossman, LLC, A Prominent Firm, Encourages Shareholders to Actively Participate
September 16, 2022
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
EQUITY ALERT: Rosen Law Firm Encourages Sema4 Holdings Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SMFR, SMFRW
September 13, 2022
From
The Rosen Law Firm, P.A.
Via
Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Sema4 Holdings Corp. (SMFR, SMFRW) Investors
September 12, 2022
From
The Law Offices of Frank R. Cruz
Via
Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses of $100,000 to Contact the Firm
September 09, 2022
Via
ACCESSWIRE
SEMA4 ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sema4 Holdings Corp. and Encourages Investors to Contact the Firm
September 08, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
SEMA4 ALERT: Bragar Eagel & Squire, P.C. is Investigating Sema4 Holdings Corp. on Behalf of Sema4 Stockholders and Encourages Investors to Contact the Firm
August 18, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Sema4 to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022
July 26, 2022
From
Sema4
Via
GlobeNewswire
